360 related articles for article (PubMed ID: 26327763)
1. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication.
Wang J; Xu ZW; Liu S; Zhang RY; Ding SL; Xie XM; Long L; Chen XM; Zhuang H; Lu FM
World J Gastroenterol; 2015 Aug; 21(32):9554-65. PubMed ID: 26327763
[TBL] [Abstract][Full Text] [Related]
2. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
[TBL] [Abstract][Full Text] [Related]
3. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
[TBL] [Abstract][Full Text] [Related]
4. The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication.
Wang J; Chen R; Zhang R; Ding S; Zhang T; Yuan Q; Guan G; Chen X; Zhang T; Zhuang H; Nunes F; Block T; Liu S; Duan Z; Xia N; Xu Z; Lu F
Theranostics; 2017; 7(12):3090-3105. PubMed ID: 28839466
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus.
Liu Y; Zhao M; Gong M; Xu Y; Xie C; Deng H; Li X; Wu H; Wang Z
Antiviral Res; 2018 Apr; 152():58-67. PubMed ID: 29458131
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
[TBL] [Abstract][Full Text] [Related]
7. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
Yang HC; Chen PJ
Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
[TBL] [Abstract][Full Text] [Related]
8. Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C.
Xu WZ; Fang Y; Li D; Wang Y; Shang QL; Li GQ; Teng X; Gu HX
World J Gastroenterol; 2008 Jun; 14(23):3733-8. PubMed ID: 18595141
[TBL] [Abstract][Full Text] [Related]
9. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo.
Lei YC; Hao YH; Zhang ZM; Tian YJ; Wang BJ; Yang Y; Zhao XP; Lu MJ; Gong FL; Yang DL
World J Gastroenterol; 2006 Jul; 12(28):4492-7. PubMed ID: 16874860
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load--down-regulated transcription of PgRNA has limited impact.
Malmström S; Larsson SB; Hannoun C; Lindh M
PLoS One; 2012; 7(7):e36349. PubMed ID: 22911677
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line.
He W; Li LX; Liao QJ; Liu CL; Chen XL
World J Gastroenterol; 2011 Mar; 17(11):1507-14. PubMed ID: 21472112
[TBL] [Abstract][Full Text] [Related]
13. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cell.
Xin XM; Li GQ; Guan XR; Li D; Xu WZ; Jin YY; Gu HX
Hepatogastroenterology; 2008; 55(88):2178-83. PubMed ID: 19260501
[TBL] [Abstract][Full Text] [Related]
15. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation.
Wei ZQ; Zhang YH; Ke CZ; Chen HX; Ren P; He YL; Hu P; Ma DQ; Luo J; Meng ZJ
World J Gastroenterol; 2017 Sep; 23(34):6252-6260. PubMed ID: 28974891
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HBV replication by delivering the dual-gene expression vector pHsa-miR16-siRNA in HepG2.2.15 cells.
Wei W; Wang SF; Yu B; Ni M
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):828-832. PubMed ID: 29270739
[TBL] [Abstract][Full Text] [Related]
17. Pregenomic RNA Launch Hepatitis B Virus Replication System Facilitates the Mechanistic Study of Antiviral Agents and Drug-Resistant Variants on Covalently Closed Circular DNA Synthesis.
Zhao Q; Chang J; Rijnbrand R; Lam AM; Sofia MJ; Cuconati A; Guo JT
J Virol; 2022 Dec; 96(24):e0115022. PubMed ID: 36448800
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of hepatitis B virus gene expression and replication by artificial microRNA.
Gao YF; Yu L; Wei W; Li JB; Luo QL; Shen JL
World J Gastroenterol; 2008 Aug; 14(29):4684-9. PubMed ID: 18698684
[TBL] [Abstract][Full Text] [Related]
19. [Dynamic analysis of HBV cccDNA in HepG2 cells infected with Ad-1.2 HBV].
Liang WF; Liu ZH; Yang J; Luo KX
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep; 27(9):1374-5. PubMed ID: 17884782
[TBL] [Abstract][Full Text] [Related]
20. [Role of tumor necrosis factor-alpha in the anti-HBV activity of tetracycline].
Ni Y; Jiang F; Xu H; Zeng T; Lei Y; Chen Y; Zhou Z; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2014 Mar; 22(3):213-8. PubMed ID: 24824125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
